Previously, it has been shown that tumor-infiltrating lymphocytes are associated with increased pCR rates and improved prognosis in several clinical trials of HER2-positive breast cancer treated with chemotherapy and trastuzumab20–23. The gene discussed is ERBB2; the disease is breast cancer.